Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections

Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections

Here, the authors identify and characterize two mouse-derived monoclonal antibodies against SARS-CoV-2 spike protein that target different epitopes in RBD and block the interaction S/ACE2 and show that a formulated humanized version cocktail exhibits prophylaxis and therapeutic antiviral effects in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chao Zhang, Yifan Wang, Yuanfei Zhu, Caixuan Liu, Chenjian Gu, Shiqi Xu, Yalei Wang, Yu Zhou, Yanxing Wang, Wenyu Han, Xiaoyu Hong, Yong Yang, Xueyang Zhang, Tingfeng Wang, Cong Xu, Qin Hong, Shutian Wang, Qiaoyu Zhao, Weihua Qiao, Jinkai Zang, Liangliang Kong, Fangfang Wang, Haikun Wang, Di Qu, Dimitri Lavillette, Hong Tang, Qiang Deng, Youhua Xie, Yao Cong, Zhong Huang
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/c3382a0b06624f9aa3dc99ff11e7fed0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Here, the authors identify and characterize two mouse-derived monoclonal antibodies against SARS-CoV-2 spike protein that target different epitopes in RBD and block the interaction S/ACE2 and show that a formulated humanized version cocktail exhibits prophylaxis and therapeutic antiviral effects in an hACE2-adenovector expressed mouse model.

Ejemplares similares